$TWST

Cho Dennis sold $1.6M of TWST

Cho Dennis (See Remarks) sold 14,205 shares of Twist Bioscience Corp (TWST) at $109.75 ($1.56M total) on 2026-08-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cho Dennis
Published Aug 7, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosure provides a concrete insider selling datapoint (shares, price, total value) but does not include new guidance, trial results, contracts, or regulatory actions.

02

Market read

Traders may briefly check for sentiment impact from insider selling, but the 10b5-1 framing suggests limited incremental information.

03

What to watch

The filing does not disclose reasons for the sale beyond the plan; without follow-on buys or company-specific news, the trading signal is weak.

Relevance 5/10Novelty 3/10Timing: filed after-hours on 2026-08-07, covering a sale dated 2026-08-05

Background

The article is an SEC Form 4 insider transaction report for Twist Bioscience, filed 2026-08-07, detailing an officer’s open-market sale under a 10b5-1 plan.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience insider Dennis Cho sold 14,205 shares at $109.75 on 2026-08-05 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be muted given the stated 10b5-1 plan.

Evidence & confidence

Form 4 shows an open-market sale with a 10b5-1 plan, which typically reduces the signal-to-noise versus discretionary selling. The filing provides transaction size and price but no new company fundamentals.

Market effects

Minimal; insider sale disclosures rarely reset sector expectations without accompanying operational or regulatory news.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so traders may ignore it.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider transaction disclosure.

  • Dennis Cho

    Officer who sold 14,205 shares at $109.75 under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.